Related Experiment Video
Updated: May 5, 2026
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
Immunomodulating effect of ethyl pyruvate on nonsyngenic transplanted tumor in mice
L A Bogdanova1, T S Morozkova, V I Kaledin
1Research Institute of Regional Pathology and Pathomorphology, Siberian Division of the Russian Academy of Medical Sciences; Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. pathol@soramn.ru. L. A. Bogdanova.
Abstract:
Indolamine-2,3-dioxygenase, a tryptophan-catabolizing enzyme, creates local conditions suppressing immune lymphocytes. Expression of this enzyme in tumors protects them from immune mechanisms, while its inhibition partially reduces tumor immunoresistance. This effect is attained by multiple subcutaneous or intraperitoneal injections of ethyl pyruvate, an indolamine-2,3-dioxygenase inhibitor. Experiments on mouse nonsyngenic tumor have demonstrated the immunomodulating effect of chronic oral ethyl pyruvate administered with drinking water.
Insights
Ethyl pyruvate, an inhibitor of indolamine-2,3-dioxygenase (IDO), can reduce tumor immunoresistance. Chronic oral administration of ethyl pyruvate demonstrated an immunomodulating effect in mouse tumor models.
Area of Science:
- Immunology
- Enzymology
- Cancer Research
Background:
- Indolamine-2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme.
- IDO expression in tumors suppresses immune lymphocytes, contributing to tumor immune evasion.
- Inhibiting IDO shows potential in overcoming tumor immunoresistance.
Purpose of the Study:
- To investigate the efficacy of ethyl pyruvate as an IDO inhibitor in reducing tumor immunoresistance.
- To evaluate the immunomodulating effects of chronic oral ethyl pyruvate administration.
Main Methods:
- Ethyl pyruvate, an IDO inhibitor, was administered via subcutaneous or intraperitoneal injections.
- Chronic oral administration of ethyl pyruvate in drinking water was tested.
- Experiments were conducted using mouse nonsyngenic tumor models.
Main Results:
- Ethyl pyruvate administration partially reduced tumor immunoresistance.
- Chronic oral ethyl pyruvate demonstrated an immunomodulating effect in vivo.
- Subcutaneous or intraperitoneal injections were effective in achieving the inhibitory effect.
Conclusions:
- Ethyl pyruvate effectively inhibits IDO, thereby reducing tumor immune evasion.
- Chronic oral administration offers a potential route for therapeutic intervention against tumor immunoresistance.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
